Yuhan USA is actively searching for business development and strategic partnership opportunities

Yuhan USA is a global business development arm of Yuhan Corporation. We are exploring collaborative opportunities and seeking partnerships with global academic research centers, biotech startups, and pharmaceutical companies.

Nov 24, 2021 · Yuhan Corporation (000100. KS) announced on the 17 th of November that the new drug candidate (YH25724) for the treatment of non-alcoholic steatohepatitis (NASH), which was licensed-out to Boehringer Ingelheim, has entered a phase 1 clinical trial in Europe.

RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.

Aug 26, 2020 · Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID).

Feb 21, 2022 · Yuhan Corporation is working together with Gunpo City, South Korea to create a high-tech bio research base and CMC center in the industrial area of Dangjeong-dong, Gunpo. Yuhan Corporation will make an investment of approximately 80 billion Won ($66.7M USD) towards the bio research center and CMC center project.

Nov 8, 2021 · Yuhan Corporation is spurring overseas open innovation expansion and strengthening its global position by continuously investing in ‘Yuhan USA’, a leading edge for global advancement.

Apr 6, 2023 · Yuhan Corporation announced on April 5, 2023, that it has signed an investment agreement to secure the largest shareholder stake in Progen Inc., a company with multi-target antibody-based platform technology.

Jul 30, 2020 · Yuhan, which formerly led the Korean pharmaceutical industry with its sales force, has transformed itself into an innovative drug developer through investment in its R&D program and in & out-license deals with biotech startups and multinational pharmaceutical companies.

May 2, 2023 · As an outpost of Yuhan’s globalization strategy, Yuhan USA is searching for business development and collaboration opportunities in new drug assets and companies that share our drive towards excellence in medicine.